Medical Pleurodesis with Povidone Iodine for Malignant Pleural Effusion in Low Income Countries

Gourti Mouad; Ouchen Fahd; Makloul Mouhsine; Maidi Elmehdi

doi:doi:10.11648/j.ijbse.20221004.12

| Peer-Reviewed

Medical Pleurodesis with Povidone Iodine for Malignant Pleural Effusion in Low Income Countries

Gourti Mouad, Ouchen Fahd, Makloul Mouhsine, Maidi Elmehdi

Published in International Journal of Biomedical Science and Engineering (Volume 10, Issue 4)

Received: 30 December 2021 Accepted: 23 May 2022 Published: 29 December 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Introduction: Chemical pleurodesis may be the best available treatment for recurrent and some pleural effusions trouble when the underlying cause cannot be treated. A wide variety of pleural irritants have been used, but the search for the ideal agent for pleurodesis continues. The aim of our study is to evaluate the efficacy and safety of iodo-povidone as an agent to treat recurrent pleural effusion. Materiel and methods: It’s a retrospective study of all cases treated in the surgery department of the regional hospital of Agadir for a recurrent pleural effusion in witch malignancy is confirmed. Results: Are included in the study 74 patients with a mean age of 61 years and a female dominance of gender. All patients in our series were symptomatic with a predominance of chest pain and dyspnea as revelatory signs. Lung cancer is the first cause incriminated in recurrent pleural effusion followed by breast cancer. All patient of the study were drained with a chest tube with caliber greater than 20 Fr and the success of the medical pleurodesis was considered in 91 % of cases with no signs of complications. Conclusion: Medical pleurodesis requires a multidisciplinary team and inter-professional communication between specialists in pulmonary medicine, thoracic surgery, and oncology, especially in patients with malignancy as an etiology of the disease. Povidone-iodine is a very effective sclerosing agent that allows effective pleural symphysis. Its cost, safety and availability represent the characteristics that have made its use especially in developing countries of major interest compared to other methods.

Published in	International Journal of Biomedical Science and Engineering (Volume 10, Issue 4)
DOI	10.11648/j.ijbse.20221004.12
Page(s)	91-93
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Pleurodesis, Pleural Symphysis, Recurrent Effusion

References

[1]	Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med. 1994 Jan 1; 120 (1): 56-64. doi: 10.7326/0003-4819-120-1-199401010-00010. PMID: 8250457.
[2]	Mierzejewski, M., Korczynski, P., Krenke, R. et al. Chemical pleurodesis – a review of mechanisms involved in pleural space obliteration. Respir Res 20, 247 (2019). https://doi.org/10.1186/s12931-019-1204-x
[3]	Kilic, D., Akay, H., Kavukçu, Ş. et al. Management of Recurrent Malignant Pleural Effusion with Chemical Pleurodesis. Surg Today 35, 634–638 (2005). https://doi.org/10.1007/s00595-005-2996-5
[4]	Lamb C, Li A, Thakkar D, Lee P. Pleurodesis. Semin Respir Crit Care Med. 2019 Jun; 40 (3): 375-385. doi: 10.1055/s-0039-1693997. Epub 2019 Sep 16. PMID: 31525812.
[5]	Dikensoy O, Light RW. Alternative widely available, inexpensive agents for pleurodesis. Curr Opin Pulm Med. 2005 Jul; 11 (4): 340-4. doi: 10.1097/01.mcp.0000166587.24127.91. PMID: 15928503.
[6]	Olivares-Torres CA, Laniado-Laborín R, Chávez-García C, León-Gastelum C, Reyes-Escamilla A, Light RW. Iodopovidone pleurodesis for recurrent pleural effusions. Chest. 2002 Aug; 122 (2): 581-3. doi: 10.1378/chest.122.2.581. PMID: 12171835.
[7]	Agarwal R, Khan A, Aggarwal AN, Gupta D. Efficacy & safety of iodopovidone pleurodesis: a systematic review & meta-analysis. Indian J Med Res. 2012 Mar; 135 (3): 297-304. PMID: 22561614; PMCID: PMC3361864.
[8]	Aelony Y. Talc pleurodesis vs iodopovidone. Chest. 2003 Apr; 123 (4): 1318-9; author reply 1319. doi: 10.1378/chest.123.4.1318. PMID: 12684335.
[9]	Guinde J, Georges S, Bourinet V, Laroumagne S, Dutau H, Astoul P. Recent developments in pleurodesis for malignant pleural disease. Clin Respir J. 2018 Oct; 12 (10): 2463-2468. doi: 10.1111/crj.12958. PMID: 30252207.
[10]	Teixeira LR, Vargas FS, Puka J, Acencio MM, Antonangelo L, Terra RM, Damico FM, Pitta FG, Marchi E. Effectiveness and safety of iodopovidone in an experimental pleurodesis model. Clinics (Sao Paulo). 2013 Apr; 68 (4): 557-62. doi: 10.6061/clinics/2013(04)19. PMID: 23778345; PMCID: PMC3634956.
[11]	Wagenfeld L, Zeitz O, Richard G. Visual loss after povidone-iodine pleurodesis. N Engl J Med. 2007 Sep 20; 357 (12): 1264-5. doi: 10.1056/NEJMc070128. PMID: 17881764.
[12]	Genofre EH, Vargas FS, Acencio MM, Antonangelo L, Teixeira LR, Marchi E. Talc pleurodesis: evidence of systemic inflammatory response to small size talc particles. Respir Med. 2009 Jan; 103 (1): 91-7. doi: 10.1016/j.rmed.2008.07.021. Epub 2008 Sep 11. PMID: 18789662.

Cite This Article

Plain Text BibTeX RIS

APA Style

Gourti Mouad, Ouchen Fahd, Makloul Mouhsine, Maidi Elmehdi. (2022). Medical Pleurodesis with Povidone Iodine for Malignant Pleural Effusion in Low Income Countries. International Journal of Biomedical Science and Engineering, 10(4), 91-93. https://doi.org/10.11648/j.ijbse.20221004.12

Copy | Download

ACS Style

Gourti Mouad; Ouchen Fahd; Makloul Mouhsine; Maidi Elmehdi. Medical Pleurodesis with Povidone Iodine for Malignant Pleural Effusion in Low Income Countries. Int. J. Biomed. Sci. Eng. 2022, 10(4), 91-93. doi: 10.11648/j.ijbse.20221004.12

Copy | Download

AMA Style

Gourti Mouad, Ouchen Fahd, Makloul Mouhsine, Maidi Elmehdi. Medical Pleurodesis with Povidone Iodine for Malignant Pleural Effusion in Low Income Countries. Int J Biomed Sci Eng. 2022;10(4):91-93. doi: 10.11648/j.ijbse.20221004.12

Copy | Download

@article{10.11648/j.ijbse.20221004.12,
  author = {Gourti Mouad and Ouchen Fahd and Makloul Mouhsine and Maidi Elmehdi},
  title = {Medical Pleurodesis with Povidone Iodine for Malignant Pleural Effusion in Low Income Countries},
  journal = {International Journal of Biomedical Science and Engineering},
  volume = {10},
  number = {4},
  pages = {91-93},
  doi = {10.11648/j.ijbse.20221004.12},
  url = {https://doi.org/10.11648/j.ijbse.20221004.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijbse.20221004.12},
  abstract = {Introduction: Chemical pleurodesis may be the best available treatment for recurrent and some pleural effusions trouble when the underlying cause cannot be treated. A wide variety of pleural irritants have been used, but the search for the ideal agent for pleurodesis continues. The aim of our study is to evaluate the efficacy and safety of iodo-povidone as an agent to treat recurrent pleural effusion. Materiel and methods: It’s a retrospective study of all cases treated in the surgery department of the regional hospital of Agadir for a recurrent pleural effusion in witch malignancy is confirmed. Results: Are included in the study 74 patients with a mean age of 61 years and a female dominance of gender. All patients in our series were symptomatic with a predominance of chest pain and dyspnea as revelatory signs. Lung cancer is the first cause incriminated in recurrent pleural effusion followed by breast cancer. All patient of the study were drained with a chest tube with caliber greater than 20 Fr and the success of the medical pleurodesis was considered in 91 % of cases with no signs of complications. Conclusion: Medical pleurodesis requires a multidisciplinary team and inter-professional communication between specialists in pulmonary medicine, thoracic surgery, and oncology, especially in patients with malignancy as an etiology of the disease. Povidone-iodine is a very effective sclerosing agent that allows effective pleural symphysis. Its cost, safety and availability represent the characteristics that have made its use especially in developing countries of major interest compared to other methods.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Medical Pleurodesis with Povidone Iodine for Malignant Pleural Effusion in Low Income Countries
AU  - Gourti Mouad
AU  - Ouchen Fahd
AU  - Makloul Mouhsine
AU  - Maidi Elmehdi
Y1  - 2022/12/29
PY  - 2022
N1  - https://doi.org/10.11648/j.ijbse.20221004.12
DO  - 10.11648/j.ijbse.20221004.12
T2  - International Journal of Biomedical Science and Engineering
JF  - International Journal of Biomedical Science and Engineering
JO  - International Journal of Biomedical Science and Engineering
SP  - 91
EP  - 93
PB  - Science Publishing Group
SN  - 2376-7235
UR  - https://doi.org/10.11648/j.ijbse.20221004.12
AB  - Introduction: Chemical pleurodesis may be the best available treatment for recurrent and some pleural effusions trouble when the underlying cause cannot be treated. A wide variety of pleural irritants have been used, but the search for the ideal agent for pleurodesis continues. The aim of our study is to evaluate the efficacy and safety of iodo-povidone as an agent to treat recurrent pleural effusion. Materiel and methods: It’s a retrospective study of all cases treated in the surgery department of the regional hospital of Agadir for a recurrent pleural effusion in witch malignancy is confirmed. Results: Are included in the study 74 patients with a mean age of 61 years and a female dominance of gender. All patients in our series were symptomatic with a predominance of chest pain and dyspnea as revelatory signs. Lung cancer is the first cause incriminated in recurrent pleural effusion followed by breast cancer. All patient of the study were drained with a chest tube with caliber greater than 20 Fr and the success of the medical pleurodesis was considered in 91 % of cases with no signs of complications. Conclusion: Medical pleurodesis requires a multidisciplinary team and inter-professional communication between specialists in pulmonary medicine, thoracic surgery, and oncology, especially in patients with malignancy as an etiology of the disease. Povidone-iodine is a very effective sclerosing agent that allows effective pleural symphysis. Its cost, safety and availability represent the characteristics that have made its use especially in developing countries of major interest compared to other methods.
VL  - 10
IS  - 4
ER  -

Copy | Download

Author Information

Gourti Mouad

Surgery Team, Medical University of Agadir, Agadir, Morrroco
Ouchen Fahd

Chest Surgery Department, Regional Hospital of Agadir, Agadir, Morrroco
Makloul Mouhsine

Chest Surgery Department, Regional Hospital of Agadir, Agadir, Morrroco
Maidi Elmehdi

Surgery Team, Medical University of Agadir, Agadir, Morrroco

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Gourti Mouad, Ouchen Fahd, Makloul Mouhsine, Maidi Elmehdi. (2022). Medical Pleurodesis with Povidone Iodine for Malignant Pleural Effusion in Low Income Countries. International Journal of Biomedical Science and Engineering, 10(4), 91-93. https://doi.org/10.11648/j.ijbse.20221004.12

Copy | Download

ACS Style

Gourti Mouad; Ouchen Fahd; Makloul Mouhsine; Maidi Elmehdi. Medical Pleurodesis with Povidone Iodine for Malignant Pleural Effusion in Low Income Countries. Int. J. Biomed. Sci. Eng. 2022, 10(4), 91-93. doi: 10.11648/j.ijbse.20221004.12

Copy | Download

AMA Style

Gourti Mouad, Ouchen Fahd, Makloul Mouhsine, Maidi Elmehdi. Medical Pleurodesis with Povidone Iodine for Malignant Pleural Effusion in Low Income Countries. Int J Biomed Sci Eng. 2022;10(4):91-93. doi: 10.11648/j.ijbse.20221004.12

Copy | Download

@article{10.11648/j.ijbse.20221004.12,
  author = {Gourti Mouad and Ouchen Fahd and Makloul Mouhsine and Maidi Elmehdi},
  title = {Medical Pleurodesis with Povidone Iodine for Malignant Pleural Effusion in Low Income Countries},
  journal = {International Journal of Biomedical Science and Engineering},
  volume = {10},
  number = {4},
  pages = {91-93},
  doi = {10.11648/j.ijbse.20221004.12},
  url = {https://doi.org/10.11648/j.ijbse.20221004.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijbse.20221004.12},
  abstract = {Introduction: Chemical pleurodesis may be the best available treatment for recurrent and some pleural effusions trouble when the underlying cause cannot be treated. A wide variety of pleural irritants have been used, but the search for the ideal agent for pleurodesis continues. The aim of our study is to evaluate the efficacy and safety of iodo-povidone as an agent to treat recurrent pleural effusion. Materiel and methods: It’s a retrospective study of all cases treated in the surgery department of the regional hospital of Agadir for a recurrent pleural effusion in witch malignancy is confirmed. Results: Are included in the study 74 patients with a mean age of 61 years and a female dominance of gender. All patients in our series were symptomatic with a predominance of chest pain and dyspnea as revelatory signs. Lung cancer is the first cause incriminated in recurrent pleural effusion followed by breast cancer. All patient of the study were drained with a chest tube with caliber greater than 20 Fr and the success of the medical pleurodesis was considered in 91 % of cases with no signs of complications. Conclusion: Medical pleurodesis requires a multidisciplinary team and inter-professional communication between specialists in pulmonary medicine, thoracic surgery, and oncology, especially in patients with malignancy as an etiology of the disease. Povidone-iodine is a very effective sclerosing agent that allows effective pleural symphysis. Its cost, safety and availability represent the characteristics that have made its use especially in developing countries of major interest compared to other methods.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Medical Pleurodesis with Povidone Iodine for Malignant Pleural Effusion in Low Income Countries
AU  - Gourti Mouad
AU  - Ouchen Fahd
AU  - Makloul Mouhsine
AU  - Maidi Elmehdi
Y1  - 2022/12/29
PY  - 2022
N1  - https://doi.org/10.11648/j.ijbse.20221004.12
DO  - 10.11648/j.ijbse.20221004.12
T2  - International Journal of Biomedical Science and Engineering
JF  - International Journal of Biomedical Science and Engineering
JO  - International Journal of Biomedical Science and Engineering
SP  - 91
EP  - 93
PB  - Science Publishing Group
SN  - 2376-7235
UR  - https://doi.org/10.11648/j.ijbse.20221004.12
AB  - Introduction: Chemical pleurodesis may be the best available treatment for recurrent and some pleural effusions trouble when the underlying cause cannot be treated. A wide variety of pleural irritants have been used, but the search for the ideal agent for pleurodesis continues. The aim of our study is to evaluate the efficacy and safety of iodo-povidone as an agent to treat recurrent pleural effusion. Materiel and methods: It’s a retrospective study of all cases treated in the surgery department of the regional hospital of Agadir for a recurrent pleural effusion in witch malignancy is confirmed. Results: Are included in the study 74 patients with a mean age of 61 years and a female dominance of gender. All patients in our series were symptomatic with a predominance of chest pain and dyspnea as revelatory signs. Lung cancer is the first cause incriminated in recurrent pleural effusion followed by breast cancer. All patient of the study were drained with a chest tube with caliber greater than 20 Fr and the success of the medical pleurodesis was considered in 91 % of cases with no signs of complications. Conclusion: Medical pleurodesis requires a multidisciplinary team and inter-professional communication between specialists in pulmonary medicine, thoracic surgery, and oncology, especially in patients with malignancy as an etiology of the disease. Povidone-iodine is a very effective sclerosing agent that allows effective pleural symphysis. Its cost, safety and availability represent the characteristics that have made its use especially in developing countries of major interest compared to other methods.
VL  - 10
IS  - 4
ER  -

Copy | Download